Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
May 20th 2024Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.
Read More
The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
May 20th 2024Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.
Read More
Looking Towards The Future of HR+/HER2- Breast Cancer
The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Read More
Practical Considerations for ADC Selection in HR+/HER2- mBC
Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.
Read More
Data Updates on Sacituzumab Govitecan
Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.
Read More
Biomarker Testing Practices in HR+/HER2- Breast Cancer
Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.
Read More
HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway
Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.
Read More
Addressing Disease Progression on ET: Data Updates and Ongoing Trials
A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.
Read More
Potential Approaches to Treatment Switching in HR+/HER2- mBC
Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.
Read More
Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice
Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
Read More
The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings
Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.
Read More
Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials
Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.
Read More
CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting
The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.
Read More
Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer
A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.
Read More
Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer
VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.
Read More
Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer
Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.
Read More
Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.
Read More
Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer
The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.
Read More
Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer
A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.
Read More
Future Directions in Care for HER2+ Breast Cancer
Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.
Read More
Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer
Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.
Read More
Novel Treatment Strategies for HER2-Low Breast Cancer
Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.
Read More
Establishing the Paradigm of HER2-Low Breast Cancer
Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.
Read More
Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer
Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.
Read More
HER2+ mBC: Practical Selection and Sequencing of Therapy
Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.
Read More
Novel Treatment Approaches to Brain Metastases in HER2+ Breast Cancer
Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.
Read More